JCO: Obesity is a delay again! Large retrospective analysis showed that chemotherapy was poor in obese breast cancer patients.

How harmful is obesity? In the case ofbreast cancer, the higher the BMI and the higher the risk of breast cancer in the Asian population before diagnosis, and after diagnosis, for every 5 kg of weight gain, the overall cause mortality rate increased by 12% and the specific mortality rate increased by 13%During treatment, obesity is also a troublemaker, see not good patientsExisting studies have shown that breast cancer patients are obese or overweight, and the effect of chemotherapy is greatly reducedAn international team of researchers based on a retrospective analysis of data from large clinical trials concluded that breast cancer patients who are overweight or obese are much less effective at receiving docitas, one of the most widely used chemotherapy drugs in the world, than the average patientTheir study was published in the Journal of Clinical Oncologyin most European countries, more than 50% of women are overweight or obese (bmi (BMI) is higher than 25 kg / m2 by WHO definition)In the United States, more than 63 percent of women do so, and the percentage is expected to increase further in the coming yearsIt is not all known that obese women have a higher risk of breast cancer and that of obese breast cancer patients who have a higher risk of recurrenceIn addition, although many cancer patients are overweight or obese, it is generally not clear how effective anticancer drugs are based on their BMIanalysis of 2,800 patients
In the study, a team of researchers from the University of Leuven in Belgium, the Jules Borde Institute in Brussels, Belgium, the University of Milan and the Italian National Cancer Institute analyzed clinical trial data from more than 2,800 breast cancer patients that began around the turn of the centuryThe study lasted more than a decade, and the researchers collected a lot of patient dataIn the trial, the patient received a combination of chemotherapy drugs with or without Dosita then, the researchers looked at how many patients relapsed and how many died Their statistical analysis of the data showed that overweight and obese patients treated with dociestathan had worse results than those who were thin (BMI 18.5 to 25 kg / m2) This difference was not observed in patients receiving chemotherapy regimens that did not include Dossita raise awareness the results have drawn attention to dossy's treatment of overweight and obese cancer patients if subsequent studies confirm that the findings are only related to the pharmacological properties of Dosita, it may also apply to patients with other types of cancer treated by Dosita, such as prostate or lung cancer The results also led researchers to question whether other chemotherapy drugs in the same family, such as yewol, would show the same effect More research is needed before changing treatment options Patients with questions about Dorsey can discuss it with their doctor Professor Biganzoli, Department of Medical Statistics and Data Science Research at the University of Milan and the Italian National Cancer Institute, said the public needed to better understand the link between BMI and breast cancer In medicine and research, researchers need to pay more attention to how obesity affects biology, progression and the efficacy of breast cancer treatment